FIA
KYMR icon

FNY Investment Advisers’s Kymera Therapeutics KYMR Stock Holding History

FNY Investment Advisers’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-334
Closed -$14K – 1388
2025
Q2 		$14K Buy
+334
New +$11.5K 0.01% 604

Other funds holding KYMR

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

FNY Investment Advisers's KYMR Position: Q3 2025 in Review

FNY Investment Advisers sold out of Kymera Therapeutics (KYMR) in Q3 2025, closing a stake of 334 shares — an estimated $14K sold.

FNY Investment Advisers first reported a position in KYMR in Q2 2025 and held it in 1 quarter. The position peaked at $14K in Q2 2025. 210 funds tracked by Wall St. Rank hold KYMR as of Q3 2025.

  • FNY Investment Advisers reported no remaining Kymera Therapeutics position as of Q3 2025 after selling out during the quarter.
  • FNY Investment Advisers sold 334 Kymera Therapeutics shares in Q3 2025, an estimated $14K.
  • FNY Investment Advisers first reported a position in Kymera Therapeutics in Q2 2025 and held it in 1 quarter.
  • FNY Investment Advisers's Kymera Therapeutics position peaked at $14K in Q2 2025.
  • 210 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2025.

Based on FNY Investment Advisers's 13F filing for Q3 2025, filed 15 Dec 2025.